爱博医疗(688050) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached CNY 1,409.80 million, a year-on-year increase of 48.22%[2] - Net profit attributable to shareholders was CNY 387.16 million, up 27.36% compared to the previous year[6] - The company’s net profit excluding non-recurring gains and losses was CNY 388.66 million, representing a growth of 34.58%[6] - The weighted average return on equity rose to 17.06%, an increase of 1.80 percentage points from the previous year[2] Asset and Capital Structure - Total assets at the end of the reporting period were CNY 3,512.69 million, reflecting a growth of 14.73% from the beginning of the period[7] - Share capital increased by 80.09% due to a capital reserve conversion plan, resulting in a share increase of 8 shares for every 10 held[8] Product Performance - The company experienced significant growth in sales of artificial crystalline lenses and orthokeratology lenses during the reporting period[8] - Revenue from vision care products, including contact lenses and care products, accounted for approximately 30% of total revenue[5] - The company's gross profit margin decreased due to price drops in artificial crystalline lenses and an increased revenue share from contact lens products[6] Audit and Reporting - The financial data presented is preliminary and subject to change upon final audit in the annual report[10]